Neuralink's Milestones in 2025 and Its Promising Future in 2026

Neuralink made remarkable progress in 2025, pushing the boundaries of brain-computer interface (BCI) technology. The company’s advances in clinical trials, funding, and device innovation have set the stage for a transformative year ahead. This post reviews Neuralink’s key achievements in 2025 and highlights what to watch for in 2026.

Breakthrough Device Designation and Speech Restoration

One of Neuralink’s most significant milestones was receiving the FDA Breakthrough Device Designation for its speech restoration technology. This device targets severe speech impairments, offering hope to patients who have lost the ability to communicate verbally. The designation accelerates regulatory review, allowing Neuralink to bring this technology to patients faster.

This breakthrough reflects Neuralink’s commitment to practical medical applications beyond experimental research. Speech restoration could dramatically improve quality of life for people with conditions like ALS, stroke, or spinal cord injuries.

Expanding Global Clinical Trials

Neuralink expanded its clinical reach beyond the United States in 2025. The company launched its first clinical trial in the Middle East, the UAE-PRIME study, at Cleveland Clinic Abu Dhabi. This trial is conducted in partnership with the Department of Health Abu Dhabi, marking a strategic collaboration to test Neuralink’s technology in a new population.

In the United Kingdom, Neuralink partnered with University College London Hospitals and Newcastle Hospitals to begin clinical trials. The first UK participant, Paul, successfully controlled a computer with his thoughts just hours after receiving an implant. This rapid demonstration of functionality highlights the device’s potential for real-world use.

Canada also saw Neuralink’s first procedures outside the US, with two patients suffering cervical spinal cord injuries receiving implants at Toronto’s University Health Network. These surgeries marked a major step in proving the device’s safety and effectiveness internationally.

Strong Financial Backing and Valuation

Neuralink raised $650 million in Series E funding during 2025. Leading investors included ARK Invest, Sequoia Capital, and Founders Fund. This round valued the company at approximately $9 billion, reflecting strong confidence in Neuralink’s technology and growth potential.

The funding will support ongoing clinical trials, research, and manufacturing scale-up. It also enables Neuralink to accelerate development of faster and safer implant procedures.

Innovations in Surgical Technology

Neuralink introduced a next-generation surgical robot with several improvements:

• Electrode thread insertion time reduced to 1.5 seconds per thread

• Increased insertion depths exceeding 50mm

• Compatibility with 99% of anatomical variations worldwide

• Manufacturing costs for needle cartridges lowered by 95%

  
  

These enhancements make the implantation process quicker, safer, and more accessible to a broader range of patients. Neuralink also announced goals to develop LASIK-like implant procedures that take only minutes, emphasizing flexible electrode threads to reduce neuron damage.

Convoy Project and Robotic Arm Control

The Convoy project tested participants controlling robotic arms using their BCIs. This work demonstrates the potential for Neuralink’s technology to restore motor function and independence for people with paralysis or limb loss. Participants have shown the ability to manipulate robotic limbs with precision, opening new possibilities for assistive devices.

Growing Participant Community

As of now, Neuralink has approximately 20 participants in its clinical trials. Some known participants include:

• Noland Arbaugh (@ModdedQuad)

• Alex Conley (@Bcidesign)

• Bradford Smith (@ALScyborg)

• Michael Melgarejo

• RJ Tanner

• Rob Greiner (@greiner_ro52817)

• Jake Schneider (@PairedWith_P7)

• Nick Wray (@Telepath_8)

• Audrey Crews (@NeuraNova9)

• Paul

• Jon L. Noble (@CheckCanopy)

  
  

This growing community provides valuable feedback and data to refine Neuralink’s devices and procedures.

What to Watch for in 2026

Neuralink’s 2025 achievements lay a strong foundation for the coming year. Key areas to watch include:

• Regulatory approvals: Progress toward FDA approval for speech restoration and other therapeutic uses

• Expanded clinical trials: More participants across multiple countries, including new patient groups

• Faster implant procedures: Development of LASIK-like surgeries that reduce time and risk

• Device improvements: Continued innovation in electrode design and surgical robotics

• Real-world applications: Increased use of BCIs for communication, mobility, and assistive technology

  
  

Neuralink’s work could transform how people with neurological impairments communicate and interact with the world. The company’s focus on safety, speed, and accessibility will be critical to broader adoption.

Final Thoughts

Neuralink’s progress in 2025 shows the company moving from experimental stages toward practical medical solutions. Its global clinical trials, breakthrough device designation, and advanced surgical technology demonstrate a clear path forward. With strong financial support and a growing participant base, Neuralink is poised to make significant strides in 2026.